y infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m 2 (24.32 mg/kg), during the time of the entire conditioning treatment.
CNS LYMPHOMAThe recommended dose is 185 mg/m 2/day (5 mg/kg/day) as a single daily infusion, administered for 2 consecutive days before autologous HPCT, without exceeding the total maximum cumulative dose of 370 mg/m 2 (10 mg/kg), during the time of the entire conditioning treatment.
MULTIPLE MYELOMA
The recommended dose ranges from 150 mg/m 2/day (4.05 mg/kg/day) to 250 mg/m 2/day
Solid tumours
The recommended dose in solid tumours ranges from 120 mg/m 2/day (3.24 mg/kg/day) to 250 mg/m 2/day (6.76 mg/kg/day) divided in one or two daily infusions, administered from 2 up to 5 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 800 mg/m 2 (21.62 mg/kg), during the time of the entire conditioning treatment.
BREAST CANCER
The recommended dose ranges from 120 mg/m 2/day (3.24 mg/kg/day) to 250 mg/m 2/day (6.76 mg/kg/day) as a single daily infusion, administered from 3 up to 5 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 800 mg/m 2 (21.62 mg/kg), during the time of
The recommended dose ranges from 125 mg/m 2/day (3.38 mg/kg/day) to 250 mg/m 2/day (6.76 mg/kg/day) divided in one or two daily infusions, administered from 3 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m 2 (20.27 mg/kg), during the time of the entire conditioning treatment.
OVARIAN CANCER
The recommended dose is 250 mg/m 2/day (6.76 mg/kg/day) as a single daily infusion, administered in 2 consecutive days before autologous HPCT, without exceeding the total maximum cumulative dose of 500 mg/m 2 (13.51 mg/kg), during the time of the entire conditioning treatment.
GERM CELL TUMOURS
The recommended dose ranges from 150 mg/m 2/day (4.05 mg/kg/day) to 250 mg/m 2/day (6.76 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m 2 (20.27 mg/kg), during the time of the entire
ALLOGENEIC HPCT:
Haematological diseases
The recommended dose in haematological diseases ranges from 185 mgm2day 5 mgkgday to 481 mgm2day 13 mgkgday divided in one or two daily infusions, administered from 1 up to 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 555 mgm2 15 mgkg, during the time of the entire conditioning treatment. LYMPHOMA The recommended dose in lymphoma is 370 mgm2day 10 mgkgday divided in two daily infusions before allogeneic HPCT, without exceeding the total maximum cumulative dose of 370 mgm210 mgkg, during the time of the entire conditioning treatment. MULTIPLE MYELOMA The recommended dose is 185 mgm2day 5 mgkgday as a single daily infusion before allogeneic HPCT, without exceeding the total maximum cumulative dose of 185 mgm |
